SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

DelMar Pharmaceuticals, Inc. (DMPI)

DMPI RSS Feed
Add DMPI Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 9/15/2016 1:06:20 PM - Followers: 18 - Board type: Free - Posts Today: 0
Del Mar Pharmaceuticals


http://www.delmarpharma.com/



Del Mar Pharma is developing new drug candidates targeting orphan cancer indications representing market opportunities in the US$100s of millions in North America and potentially billions of dollars worldwide. We aim to develop products that will have a high impact in patient care and a high return for our investors.
In order to accelerate our development timelines and reduce technical risk, we leverage existing clinical and commercial data from a wide range of sources. This business model has been well validated and demonstrated to position for investor exit with significant upside, even prior to commercialization.
 

Key elements of our business strategy include:

  • Leveraging existing human clinical data to support new regulatory filings with the U.S. FDA, Health Canada and the European Medicines Agency (EMEA).
  • Advancing our products into orphan drug indications where patients are failing modern biologic or targeted therapy in order to obtain a guarantee of market exclusivity, attractive reimbursement, and high-likelihood of accelerated product approvals.
  • Establishing new intellectual property around our product candidates, including use, manufacturing, chemical composition and mechanism patent claims.
  • Obtaining commercial drug product from existing commercial manufacturers to accelerate entry into human clinical trials and reduce development costs.
  • Investigating the molecular mechanism of our drug candidates in order to establish additional patent claims and also to identify patients most likely to benefit from therapy (personalized medicine approach).
  • Commercializing our products through a combination of direct marketing and collaborative partnerships. For example, we target marketing our products to the small number of leading cancer centers in North America who specialize in the treatment of resistant orphan cancers and establishing sales and marketing partnerships for "large volume" tumor markets and in international markets including Europe & Asia.
  • Generating near-term revenue by leveraging opportunities in markets where our drug candidates are already approved or can be readily registered.
  • Operating on a "virtual" basis to minimize fixed-research costs while maintaining access to a highly-experienced and skilled workforce.


Product Development Programs: VAL-083

Del Mar Pharma's first product candidate, VAL-083, benefits from an historical investment of more than US$50 million by the National Cancer Institute (NCI) in the United States. The drug is well-characterized and has been studied in more than 40 Phase I & Phase II NCI-sponsored human clinical trials in the United States and in Europe. VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and solid tumors, including lung cancer.

 

http://www.delmarpharma.com/DelMarPharma_Presentation_Jan2013.pdf

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
DMPI
Current Price
Volume:
Bid Ask Day's Range
SureTrader
DMPI News: Securities Registration (section 12(b)) (8-a12b) 07/08/2016 07:47:02 AM
DMPI News: Current Report Filing (8-k) 05/20/2016 02:31:47 PM
DMPI News: Current Report Filing (8-k) 05/19/2016 02:01:14 PM
DMPI News: Quarterly Report (10-q) 05/12/2016 04:15:18 PM
DMPI News: Small Company Offering and Sale of Securities Without Registration (d) 05/10/2016 01:58:24 PM
PostSubject
#168   Hi Jssdmm, Hope all is well. I haven't had Rkmatters 09/15/16 01:06:20 PM
#167   Hi RKMatters. jssdmm 09/12/16 06:46:50 PM
#166   DelMar Pharmaceuticals and Accurexa to Collaborate in the Rkmatters 09/07/16 08:52:37 AM
#165   http://ir.delmarpharma.com/press-releases/detail/829 Rkmatters 08/30/16 01:07:33 PM
#164   Possibly. $6.23 is now the BOLLINGER bottom. But Rkmatters 07/29/16 04:02:13 PM
#163   Under 6 coming? Jumpinjackas 07/29/16 03:05:38 PM
#162   Great post. Agree. Rkmatters 07/29/16 11:42:41 AM
#161   I agree. Also, the phase 3 trial design jssdmm 07/29/16 11:29:25 AM
#160   Yeah, but I see a few steps forward, Rkmatters 07/28/16 12:07:51 AM
#159   Back down it goes Jumpinjackas 07/27/16 03:40:54 PM
#158   DMPI News: Securities Registration (section 12(b)) (8-a12b) 07/08/2016 07:47:02 mick 07/21/16 12:45:54 PM
#157   now nasdaq/ Delmar Pharmaceutica (DMPI) mick 07/21/16 12:45:48 PM
#156   So cool. :) Rkmatters 07/14/16 09:18:22 AM
#155   Join me in the celebration! ;) undtrdr 07/14/16 09:03:59 AM
#154   DMPI moved to the Nasdaq from the OTC Renee 07/12/16 08:48:14 AM
#153   A successful uplist thus far. Wait until the Rkmatters 07/11/16 10:29:47 AM
#152   Welcome to the Nasdaq! - ringing the opening undtrdr 07/11/16 08:55:58 AM
#151   Don't forget to add "breakthrough status". I Rkmatters 06/17/16 11:23:15 AM
#150   Shorting or Selling DMPI stock right now is biotechrulz 06/17/16 08:28:09 AM
#149   You think TTFields is worse than chemo from Jumpinjackas 06/16/16 11:34:58 PM
#148   I'm honestly not very interested in it, from Rkmatters 06/16/16 07:19:54 PM
#147   What do you think of TTFields? I'm looking into Jumpinjackas 06/16/16 06:53:22 PM
#146   You are plenty early. There are warrants. Rkmatters 06/16/16 06:20:27 PM
#145   My valuation does not include any of that! Rkmatters 06/16/16 06:16:03 PM
#144   I know man. I missed it when it Jumpinjackas 06/16/16 06:16:00 PM
#143   Yes, I agree that DMPI is severely undervalued jssdmm 06/16/16 05:59:41 PM
#142   That price before the buyout. :) Rkmatters 06/16/16 05:39:07 PM
#141   This gained close to 200% in the last Rkmatters 06/16/16 05:38:09 PM
#140   Getting hammered. Jumpinjackas 06/16/16 01:04:58 PM
#139   Poster from ASCO...http://www.delmarpharma.com/ASCO%202016%20clinical%20-%2090(w imadigger 06/05/16 07:17:46 PM
#138   DMPI: effective May 20,2016 a one for 4 Renee 05/19/16 09:36:30 AM
#137   I'm holding mine. :) Rkmatters 05/17/16 03:26:05 PM
#136   I AGREE THAT SELLING HERE WOULD NOT BE co pilot 05/17/16 10:38:01 AM
#135   A lot of big catalysts this year for DMPI... biotechrulz 05/17/16 09:30:10 AM
#134   THAT'S JUST IT, WITH ALL THIS GREAT NEWS co pilot 05/17/16 09:19:54 AM
#133   You are so clueless, this stock is not biotechrulz 05/16/16 04:48:56 PM
#132   CO-PILOT SOUNDS LIKE A BITTER SELLER OF DMPI biotechrulz 05/16/16 04:44:40 PM
#131   LOOKS AS IF THERE ARE BIG SELLERS WHO co pilot 05/16/16 02:55:42 PM
#130   LIKE I SAID EARLIER, DMPI WILL NOT CLOSE co pilot 05/16/16 02:21:23 PM
#129   Why because you say so? You sound biotechrulz 05/13/16 11:46:57 AM
#128   Excellent news by DMPI today...... biotechrulz 05/13/16 09:18:43 AM
#127   DMPI, NEEDS TO GET PAST $1.50 AND STAY co pilot 05/12/16 12:44:27 PM
#126   DelMar Pharmaceuticals, Inc. Announces $5.6 Million Private Placement Rkmatters 05/05/16 08:44:46 AM
#125   I complete agree. The management team is steadily jssdmm 04/21/16 02:14:12 PM
#124   Mechanism Manners - a blog posted by CEO undtrdr 04/21/16 11:31:18 AM
#123   Read this last night. Great blog on the Rkmatters 04/21/16 09:04:36 AM
#122   They are going for base hits and will Rkmatters 04/21/16 09:02:51 AM
#121   3rd ODD designation for VAL -083! Ovarian Cancer undtrdr 04/21/16 08:32:38 AM
#120   http://www.thechairmansblog.com/delmar-pharmaceuticals/jeffrey-bacha/mechanism-m undtrdr 04/20/16 01:42:15 PM
#119   DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Rkmatters 04/19/16 10:48:07 AM
PostSubject